- Home
- MAIA vs ANL Comparison
MAIA vs ANL Comparison
Compare MAIA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- ANL
- Stock Information
- Founded
- MAIA 2018
- ANL 2004
- Country
- MAIA United States
- ANL Cayman Islands
- Employees
- MAIA N/A
- ANL N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- MAIA Health Care
- ANL
- Exchange
- MAIA Nasdaq
- ANL Nasdaq
- Market Cap
- MAIA 46.7M
- ANL 51.7M
- IPO Year
- MAIA 2022
- ANL 2023
- Fundamental
- Price
- MAIA $1.85
- ANL N/A
- Analyst Decision
- MAIA
- ANL Hold
- Analyst Count
- MAIA 0
- ANL 1
- Target Price
- MAIA N/A
- ANL N/A
- AVG Volume (30 Days)
- MAIA 543.2K
- ANL 8.3K
- Earning Date
- MAIA 08-08-2025
- ANL 08-08-2025
- Dividend Yield
- MAIA N/A
- ANL N/A
- EPS Growth
- MAIA N/A
- ANL N/A
- EPS
- MAIA N/A
- ANL N/A
- Revenue
- MAIA N/A
- ANL N/A
- Revenue This Year
- MAIA N/A
- ANL N/A
- Revenue Next Year
- MAIA N/A
- ANL N/A
- P/E Ratio
- MAIA N/A
- ANL N/A
- Revenue Growth
- MAIA N/A
- ANL N/A
- 52 Week Low
- MAIA $1.40
- ANL $1.10
- 52 Week High
- MAIA $4.24
- ANL $4.10
- Technical
- Relative Strength Index (RSI)
- MAIA 53.36
- ANL 43.98
- Support Level
- MAIA $1.82
- ANL $1.47
- Resistance Level
- MAIA $2.03
- ANL $1.57
- Average True Range (ATR)
- MAIA 0.12
- ANL 0.09
- MACD
- MAIA 0.02
- ANL 0.01
- Stochastic Oscillator
- MAIA 58.14
- ANL 34.29
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.